Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | -16.29% |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | 91.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.41% |
| Mar 31, 2026 | 66.84% |
| Dec 31, 2025 | 61.01% |
| Sep 30, 2025 | 94.08% |
| Jun 30, 2025 | 42.02% |
| Mar 31, 2025 | 70.80% |
| Dec 31, 2024 | 61.06% |
| Sep 30, 2024 | 62.97% |
| Jun 30, 2024 | 64.96% |
| Mar 31, 2024 | 26.29% |
| Dec 31, 2023 | 25.12% |
| Sep 30, 2023 | 15.17% |
| Jun 30, 2023 | 18.91% |
| Mar 31, 2023 | -10.52% |
| Dec 31, 2022 | 74.57% |
| Sep 30, 2022 | 98.21% |
| Jun 30, 2022 | 97.11% |
| Mar 31, 2022 | 96.68% |
| Dec 31, 2021 | 91.14% |
| Sep 30, 2021 | -71.87% |